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Adult T cell leukemia/lymphoma (ATL) is one 
of the rare human cancers initiated by a trans-
forming retrovirus (Matsuoka and Jeang, 2007). 
The viral transactivator protein Tax was pro-
posed to be an oncogene in ATL, but the fact 
that Tax protein expression is undetectable in 
circulating ATL cells has led to significant con-
troversies (Asquith et al., 2000). However, Tax 
expression in T cells of transgenic mice or in 
human  CD34+  stem  cells  induces  leukemias 
with striking ATL-like features, including con-
stitutive  NF-B  activation,  formally  demon-
strating that Tax initiates ATL (Portis et al., 2001; 
Hasegawa et al., 2006; Banerjee et al., 2010). 
Whether continuous Tax expression is required 
for maintenance of the transformed phenotype 
is not known. Antiretroviral agents such as zido-
vudine and IFN- have shown some efficacy   
in ATL patients (Gill et al., 1995; Hermine   
et al., 1995), with complete clinical and hemato-
logical responses, although maintenance therapy 
is required to avoid relapses. Thus, even though 
the disease may be controlled, it is not cured by 
this combination. Indeed, human ATL still car-
ries a dismal long-term prognosis (Bazarbachi 
et al., 2004). Ex vivo, in HTLV-I (human T cell 
lymphotropic virus type I)–infected human ATL   
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Chronic HTLV-I (human T cell lymphotropic virus type I) infection may cause adult T cell 
leukemia/lymphoma (ATL), a disease with dismal long-term prognosis. The HTLV-I transac-
tivator, Tax, initiates ATL in transgenic mice. In this study, we demonstrate that an As2O3 
and IFN- combination, known to trigger Tax proteolysis, cures Tax-driven ATL in mice. 
Unexpectedly, this combination therapy abrogated initial leukemia engraftment into sec-
ondary recipients, whereas the primary tumor bulk still grew in the primary hosts, only to 
ultimately abate later on. This loss of initial transplantability required proteasome function. 
A similar regimen recently yielded unprecedented disease control in human ATL. Our dem-
onstration that this drug combination targeting Tax stability abrogates tumor cell immor-
tality but not short-term growth may foretell a favorable long-term efficiency of this 
regimen in patients.
© 2010 El Hajj et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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exactly  as  in  primary  human ATLs  (Matsuoka  and  Jeang, 
2007). Indeed, Tax messenger RNA levels were very similar 
in primary mouse and human ATL cells, but 1,000-fold 
higher in HuT-102 cells, in which Tax protein was easily de-
tected (Fig. 1 A and Fig. S1 B).
Mice with well-established leukemias, which had been 
inoculated 18 d earlier with ATL cells derived from any one 
of the three independent transgenic founders, were then treated 
for 3 d with IFN-, As2O3, or both (Fig. 1). Such short   
IFN-/As2O3 treatment induced a sharp decrease in the num-
ber of circulating ATL cells, which, interestingly, was no longer 
noted when a proteasome inhibitor (PS-341) was concomi-
tantly administered (Fig. 1 B and Fig. S1 C). In contrast, the 
treatment only marginally affected the spleen weight (Fig. S1 D) 
and modestly increased baseline apoptosis levels (see Fig. 3 B). 
Yet, complete reversal of NF-B activation was observed in 
ATL spleen cells (Fig. 1 C), as previously observed in human 
ATL  cell  lines  (El-Sabban  et  al.,  2000),  whereas  calcium 
plasma levels returned to normal (Fig. 1 D). Even 6-d IFN-/
As2O3 treatment did not significantly decrease the spleen 
weight (Fig. 1 E and Fig. S1 E). Thus, in contrast to the ex vivo 
setting, murine ATLs kept on growing under treatment and 
did not undergo massive and immediate apoptosis.
To investigate any survival benefit, mice were treated ear-
lier, from day 6 to 30 after inoculation of ATL cells. A limited 
advantage was seen in mice receiving IFN- or As2O3 alone, 
but a cure (>500-d survival) was noted only among those re-
ceiving  IFN-/As2O3,  and  this  occurred  more  frequently 
when a second course of therapy was administered (T1 + T2; 
Fig. 1 F). Protocols in which mice were treated only for 5 d 
per wk never resulted in a cure (unpublished data), pointing 
to the importance of continuous drug exposure. To follow the 
fate of ATL cells in the course of this curative therapy, we sac-
rificed mice at different time points after treatment initiation 
(Fig. 2 A). Again, at all time points, treatment only moderately 
affected the spleen weight (Fig. 2 B) but always resulted in   
diminished circulating ATL cells (not depicted). Pathology 
examination demonstrated persistent tissue invasion and pro-
liferation even at day 26. Although the frequency of mitoses 
in leukemic infiltrates of the spleen and liver decreased (Fig. 2, C 
and D; and Fig. S2 A), Ki-67 expression was maintained. Even 
though IFN-/As2O3 treatment did not clear the disease, it 
nevertheless significantly reduced micrometastases within si-
nusoids of the liver parenchyma (Fig. S2 B). At day 30, when 
treatment  was  discontinued,  half  of  the  examined  mice 
showed residual actively proliferating leukemic cell invasion, 
whereas the others exhibited large zones of necrosis with 
only a few remaining tumor cells and regrowth of normal   
tissue (not depicted), likely distinguishing cured mice from 
those that would ultimately die (Fig. 1 F). Importantly, blood 
cell counts remained highly abnormal when IFN-/As2O3 
therapy was discontinued in ultimately cured mice, even in 
those with rare remaining tumor cells in histological sections 
(Fig. S2 C). However, at day 180, surviving animals were   
indistinguishable from noninoculated controls (unpublished 
data). NF-B shutoff would be expected to sensitize cells to 
cell-lines, As2O3 shuts off constitutive NF-B activation   
and potentiates the apoptotic effects of IFN-, at least in part 
through Tax proteasomal degradation (Bazarbachi et al., 1999; 
El-Sabban et al., 2000; Nasr et al., 2003). Very recently, a regi-
men combining As2O3, IFN-, and zidovudine has resulted in 
unprecedented disease control in de novo patients with the 
chronic form of the disease (Kchour et al., 2009). Importantly, 
this regimen does not induce rapid tumor regression and mas-
sive cell death, questioning the cellular mechanisms involved. 
Leukemia-initiating cells (LICs; Dick, 2008) have the unique 
property to allow full leukemia development and to self- 
renew. These rare cells may be quantified by limiting dilu-
tions in secondary transplants, and their therapeutic targeting 
remains a challenge. Yet, in some mouse or human tumor   
models, most cells appear to have tumor-initiating activity, 
questioning  the  hierarchical  model  established  in  myeloid 
leukemias (Kelly et al., 2007; Quintana et al., 2008). In acute 
promyelocytic leukemia (APL), degradation of the PML/reti-
noic acid receptor  (RARA) oncogene by the combined   
effect of retinoic acid and As2O3 induces very rapid LIC clear-
ance and definitive cures (Nasr et al., 2008; Hu et al., 2009; 
Kogan, 2009). Yet, this model is complicated by the fact that 
differentiation concomitantly clears the tumor bulk. Rapid 
treatment-induced clearance of tumor-initiating activity that 
does not initially affect the tumor bulk has never been reported. 
We performed preclinical experiments in a murine transplanta-
tion model of ATL that demonstrate that an IFN-/As2O3 
combination abrogates immortal growth and triggers delayed 
apoptosis, resulting in the cure of ATL recipients. Paradoxically, 
this drug combination only marginally affects short-term cell 
proliferation or survival. These results provide a biological basis 
accounting for the clinical success of IFN-/As2O3/zidovudine 
therapy in ATL patients.
RESULTS AND DISCUSSION
To explore the in vivo efficacy of IFN-/As2O3, we estab-
lished ATL transplantation models in which 106 ATL spleen 
cells  from  one  of  three  independent  Tax  transgenic  mice 
(Hasegawa et al., 2006) were inoculated into SCID mice. All 
recipients rapidly developed massive hyperleukocytosis, sple-
nomegaly, hypercalcemia, and multiple organ invasion, identical 
to what is observed in transgenics, and they died within 1 mo 
(unpublished data). These ATL could be serially passaged for 
years, with very constant time to death in all recipients, point-
ing to the remarkable stability of this murine ATL model. We 
first questioned whether murine ATL cells responded ex vivo 
to the IFN-/As2O3 combination in the same manner as human 
ATL cell lines, in which this combination degrades Tax   
(Fig. 1 A; Bazarbachi et al., 1999; El-Sabban et al., 2000; Nasr 
et al., 2003). IFN- or As2O3 triggered apoptosis in <20% 
Tax transgenic cells. Their combination killed >80% of cells 
after ex vivo overnight exposure, whereas normal murine 
lymphocytes were marginally affected (Fig. S1 A). Tax degra-
dation by the proteasome could not be demonstrated in these 
ATL cells because the baseline level of protein was undetect-
able by Western blot analysis (Fig. S1 B; Hasegawa et al., 2006), JEM VOL. 207, December 20, 2010  2787
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(Fig. 3 B and Fig. S3 D). Yet, survival 
of  secondary  recipients  inoculated 
with ATL cells from IFN-/As2O3-
treated primary recipients was dra-
matically  increased  with  the  three 
independent murine ATLs examined 
(Fig. 3 C and Fig. S3 C). Comparing the survival of second-
ary recipients of limiting-dilution inoculates from treated or 
untreated mice established that IFN-/As2O3 dramatically 
decreased the ability of ATL cells to initiate leukemia (Fig. 3 D). 
Indeed, between 1 and 3 ATL cells from untreated donors al-
lowed ATL development, whereas around 1,000 were re-
quired when donors had received IFN-/As2O3. Critically, 
no ATL ever developed in 10 tertiary recipients inoculated 
with ATL cells from secondary mice inoculated with cells 
from IFN-/As2O3-treated primary recipients (Fig. 3 E and 
not depicted).
When  moribund  secondary  recipients  were  sacrificed, 
tumor loads (as determined by spleen weight) were slightly 
decreased in those that had received inoculates from IFN-/ 
As2O3-treated primary recipients (unpublished data). Critically, 
massive apoptosis was constantly noted in all six untreated 
leukemic  secondary  recipients  of ATL  cells  from  three   
independent  IFN-/As2O3-treated  primary  recipients  but 
not in any of the six secondary recipients from untreated do-
nors (Fig. 3 B). Cells derived from infiltrated spleen of these 
secondary recipients were bona fide ATL cells, as assessed by 
the fact that they all carried the Tax transgene (Fig. S3 F) 
and had typical morphology (Fig. S3 G and not depicted). 
apoptosis (Portis et al., 2001). Some terminal deoxynucleo-
tidyl transferase–mediated nick end labeling (TUNEL) label-
ing was noted at days 21 and 26 in vivo (Fig. 2 D and Fig. S2 A) 
but was massively increased at day 26 ex vivo (Fig. 2 E). 
Note that TUNEL positivity was always more pronounced in 
ex vivo than in in vivo labeled cells, possibly because lack of 
cell to cell contacts precipitates apoptosis. Thus, IFN-/As2O3 
elicits delayed apoptosis, which is most likely responsible for 
the ultimate ATL eradication. Collectively, the IFN-/As2O3 
combination cures Tax-driven ATLs, but the tumor grows for 
weeks under therapy, and it is fully cleared only after treat-
ment discontinuation.
Such a paradoxical pattern of response to therapy in an 
immunodeficient animal clearly sets this combination aside 
from most classical cytotoxic anticancer regimens. Thus, we 
performed serial transplantation experiments in which simi-
lar amounts of leukemic spleen cell inoculates from mice un-
treated or treated for only 3 d with IFN- and/or As2O3 
were injected into secondary recipients, which were not sub-
sequently treated (Fig. 3 A). Even when derived from IFN-
/As2O3-treated mice, cells used for inoculations were all Tax 
positive (Fig. S3 A) and were still cycling (Fig. S3 B), and their 
ex vivo TUNEL labeling was only very modestly increased 
Figure 1.  A treatment combining IFN- 
and As2O3 can cure murine ATL. (A) West-
ern blot analysis of Tax and actin protein ex-
pression in human ATL-derived HuT-102 cells 
after 48 h treatment with As2O3 (As), IFN-, 
or a combination thereof. (B–D) Effect, at day 
18 after inoculation of SCID mice with Tax 
transgenic splenocytes, of 3-d IFN- + As2O3 
treatment on circulating leukemia cell num-
bers (n = 3 for each condition; B). Normal 
SCID mice were not injected with Tax trans-
genic splenocytes. NF-B activation (C) and 
calcemia (n = 4; D) are shown. ATL denotes 
untreated animals, and PS-341 denotes the 
proteasome inhibitor. (E) Effect, at day 12 
after inoculation of SCID mice with Tax trans-
genic splenocytes, of 6-d IFN- + As2O3 treat-
ment on spleen weight (n = 3). Normal SCID 
mice were not injected with Tax transgenic 
splenocytes. (B, D, and E) Error bars show 
mean ± SD. (F) Kaplan–Meier analysis of  
overall survival curves of the murine ATL 
transplant recipients (n = 10 for each  
condition). P-values are indicated. T1 denotes 
treatment from day 6 to 30; T2 indicates  
additional treatment from day 42 to 54.  
This experiment was reproduced three times 
with similar results.2788 Selective loss of leukemia-initiating activity | El Hajj et al.
As control, we evaluated the effect of the IFN-/As2O3 
combination in other leukemias. We found that, in secondary 
transplant  experiments  identical  to  the  ones  previously   
performed with ATL cells, PML/RARA-, promyelocytic 
leukemia zinc finger protein (PLZF)/RARA- or MLL/ENL-
transformed  cells  were  marginally  (PML/RARA)  or  not 
(PLZF/RARA and MLL/ENL) affected by this treatment 
(Fig. 3 F). This demonstrates that the IFN-/As2O3 combina-
tion does not have a general deleterious activity on LIC self-
renewal outside of the context of ATL.
That IFN-/As2O3 targets immortal growth in Tax-driven 
murine ATLs could augur a favorable long-term outcome   
for As2O3/IFN-/zidovudine-treated chronic ATL patients 
(Kchour et al., 2009). In that sense, although these patients   
received a suboptimal 5-d-per-wk treatment, three out of   
six are still in continuous complete remission 7–18 mo after 
Of note, when proteasome activity was inhibited by PS-341 
during the primary recipients’ 3-d IFN-/As2O3 therapy, en-
hanced survival of secondary recipients was curtailed (Fig. 3 C  
and Fig. S3 C). PS-341 also reversed IFN-/As2O3-induced   
enhanced apoptosis of ATL cells in the three secondary   
recipients  tested  (Fig.  3  B).  Finally,  all  10  tertiary  mice 
inoculated with ATL cells derived from PS-341/IFN-/
As2O3-treated primary donors rapidly died of ATL (Fig. 3 E),   
in contrast to those with active proteasome. Collectively, a   
brief exposure to IFN-/As2O3 elicits proteasome-mediated and 
reversible inheritable cellular changes that preclude long-term 
tumor propagation but does not affect short-term survival 
or growth. These cellular changes ultimately result in delayed 
apoptosis and ATL exhaustion. Such a heritable change could 
reflect genetic alterations, epigenetic modifications, or some 
other causes that are yet to be investigated.
Figure 2.  The IFN- + As2O3 combination elicits a moderate decrease of organ infiltration. (A) Experimental design: mice were treated from  
day 6 up to day 30 after inoculation of ATL cells and sacrificed at different time points after treatment initiation. (B) Spleen weight at various time points 
during treatment (N: n = 3; ATL: d7, n = 1; and d21, n = 5; and IFN- + As2O3 [As]: d21, n = 8; d26, n = 6; d30, n = 6; and d180, n = 2). Error bars show 
mean ± SD. (C) Histological analysis of the spleen and liver of untreated recipients or at day 26 of IFN- + As2O3 therapy. (D) Ki-67 and TUNEL labeling of 
spleen leukemia cell infiltrates of untreated recipients or at day 26 of IFN- + As2O3 therapy. (E) TUNEL analysis of ATL cells infiltrating the spleen in un-
treated recipients or after 26 d of IFN- + As2O3 therapy. Bars: (C) 150 µm; (D) 50 µm.JEM VOL. 207, December 20, 2010  2789
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Figure 3.  Loss of leukemia-initiating activity accounts for the therapeutic effect of the IFN- + As2O3 combination. (A) Experimental design: 
serial transplantation of splenocytes from primary mice left untreated or after 3-d IFN- + As2O3 treatment into secondary and tertiary recipients, which 
were not subsequently treated. (B) TUNEL staining of splenocytes from primary mice left untreated (ATL) or after 3-d IFN- + As2O3 treatment (left) and 
of splenocytes from secondary recipients of ATL cells from untreated (ATL) or treated primary mice (n = 6 for control or IFN- + As2O3 [As]; n = 3 for  
PS-341 or IFN- + As2O3 + PS-341); the p-value is indicated. Secondary recipient cells were analyzed at the time of death of the mice. Secondary mice 
were not treated. (C) Effect of indicated 3-d treatment of primary donor mice on the survival of secondary recipients of 106 spleen ATL cells (n = 9 for 
each condition). This experiment was reproduced twice with similar results, as well as with two other independent primary ATLs (Fig. S3 C). (D) Survival of 
secondary recipient mice inoculated with varying initial amounts of ATL cells from primary mice either untreated or treated with IFN- + As2O3 for 3 d  
(n = 10 for each condition). (E) Effect of 3-d treatment of primary mice on the survival of tertiary transplants (n = 10 for each condition). Secondary re-
cipients were inoculated with 106 spleen ATL cells from primary mice. Tertiary recipients were inoculated with 106 spleen ATL cells from untreated second-
ary recipients. Tertiary mice were not treated. (F) Effect of 3-d treatment of primary mice on the survival of secondary recipients of leukemic cells from 
PML/RARA, PLZF/RARA APLs, or MLL/ENL leukemia (n = 3 for each condition). (B–F) Error bars show mean ± SD.2790 Selective loss of leukemia-initiating activity | El Hajj et al.
in which de novo ATL patients were treated with an As2O3/ 
IFN-/zidovudine combination, using suboptimal 5-d-per-wk 
As2O3 administration, has nevertheless yielded unprecedented 
results (Kchour et al., 2009). Interestingly, in these patients, the 
kinetics of disease clearance were significantly slower than tumor 
debulking with cytotoxic drugs. Only partial responses were ob-
served on day 30, and complete remissions slowly unfurled over 
the next month, whereas three of six patients have remained off 
treatment for months and are still disease free. These clinical ob-
servations are fully in line with the delayed apoptosis observed in 
ATL mice. That IFN-/As2O3 abrogates immortal growth in 
Tax-driven murine ATLs, together with the favorable current 
evolution of many As2O3/IFN-/zidovudine-treated ATL pa-
tients, raises the prospect of a possible cure of ATL.
MATERIALS AND METHODS
Mice. We used the ATL mouse model of Hasegawa et al. (2006). To test the 
effect of different targeted therapies, we established a rapid and reproducible 
model of disease by direct intraperitoneal transfer of 106 spleen cells from Tax 
transgenic mice into SCID mice (Charles River). Tax expression was detect-
able only at very low levels by quantitative PCR. PML/RARA and PLZF/
RARA APLs were described previously and propagated exactly as before 
(Nasr et al., 2008). MLL/ENL leukemias were derived from retrovirus infec-
tion of primary progenitors from 5-fluorouracyl–treated mice (Lavau et al., 
2000). All murine protocols were approved by the Institutional Animal Care 
and Utilization Committee of the American University of Beirut and the   
Institut Universitaire d’Hématologie (Université Paris Diderot). All animals 
were housed in specific pathogen-free facilities. Animals were sacrificed by 
cervical dislocation after deep anesthesia with isoflurane.
Treatments. As2O3 was obtained from Sigma-Aldrich, and recombinant   
human IFN- (Roferon) was obtained from Roche. The proteasome inhibi-
tor PS-341 or bortezomib (Velcade) was purchased from Millennium Phar-
maceuticals.  For  in  vivo  experiments,  mice  received  As2O3  (5  µg/g/d) 
intraperitoneally, IFN- (106 IU/d) subcutaneously, and bortezomib (0.5 mg/
kg/d) through mini-osmotic pumps (Alzet; Charles River). These doses are 
comparable with those used in other mouse models and predicted to yield 
plasma concentrations similar to those noted in patients (Lallemand-Breitenbach 
et al., 2008; Nasr et al., 2008; Kogan, 2009). None of the individual or com-
bination treatment regimens were toxic in normal SCID mice (100% sur-
vival for >3 mo; n = 3 for each condition). In ex vivo experiments, malignant 
cells from Tax transgenic mice were treated in vitro with 1 µM As2O3, 1,000 
IU IFN-, or a combination of both for up to 48 h. Note that the regimen 
used in ATL mice did not comprise zidovudine because Tax is under the 
control of the Lck promoter, rather than being expressed from the retrovirus. 
Treatment protocols for patients with ATL were approved by the ethical 
committee of Mashhad University of Medical Sciences.
Histopathological  and  laboratory  examination. Tissues  from  either 
treated or untreated mice were fixed in neutral buffer formalin (Sigma- 
Aldrich), embedded in paraffin, sectioned, stained with hematoxylin and   
eosin, and examined by light microscopy. Ki-67 expression was assessed by 
immunohistochemistry using rat anti–mouse monoclonal antibodies. Peripheral 
blood smears were prepared using Giemsa staining. WBC counts and serum 
calcium levels were determined using routine clinical laboratory techniques. 
The TUNEL assay was performed on deparaffinized 5-µm sections treated 
with 20 µg ml1 proteinase K for 15 min at room temperature. The number 
of TUNEL-positive cells was assessed by two pathologists in three different 
microscopic fields for each organ studied (liver, lung, and spleen) on a micro-
scope (ProvisAX70; Olympus) with wide-field eye-piece number 26.5 at 600 
magnification,  which  provides  a  field  size  of  0.244  mm2.  Mitoses  were 
counted with the same methods, and the results were expressed as the mean 
number of apoptotic cells or of mitoses per field at 600 magnification.
discontinuing maintenance therapy, whereas five ATL patients 
previously treated with IFN-/zidovudine alone all relapsed, 
on average, in less than 5 mo after treatment discontinuation 
(Table S1). Similarly, in an ongoing trial of ATL lymphoma pa-
tients, all six assessable patients are still in complete remission 
with 3–84-mo follow up after As2O3/IFN- consolidation 
therapy after initial chemotherapy, which is a distinctly uncom-
mon finding (unpublished data). Although preliminary, these 
observations suggest nonetheless that in patients, As2O3/IFN-  
also efficiently targets ATL immortal growth.
To our knowledge, the data presented in this study are the 
first to decipher the uncoupling between treatment-induced 
loss of transplantability and continued proliferation of the   
tumor bulk, which ultimately results in leukemia eradication. 
Tax-driven murine ATL resembles Myc-driven lymphomas or 
human melanomas, as most cells can initiate tumor formation 
(Kelly et al., 2007; Quintana et al., 2008). This suggests that the 
IFN-/As2O3 combination initiates irreversible changes that 
preclude immortal growth but not short-term proliferation. 
These changes may restore unidentified checkpoints (such as 
P53), possibly through epigenetic modifications. Such check-
point activation triggers delayed apoptosis, as shown both by 
time course analysis (Fig. 2 E) and transplantation experiments 
(Fig. 3, C and D). That this delayed apoptosis is fully protea-
some  dependent  strongly  suggests  the  contribution  of Tax 
degradation in the process, hence the specificity of IFN-/
As2O3  for  ATL  cells  ex  vivo  (Bazarbachi  et  al.,  1999;   
El-Sabban et al., 2000; Nasr et al., 2003) or in vivo (Fig. 3 F). 
Unfortunately, technical issues of sensitivity preclude the for-
mal demonstration of Tax degradation in vivo and thus defini-
tive conclusion as to the mechanism involved in the effect of 
therapy. Nevertheless, our data point to the possibility that, in 
the same manner as in the APL model (Nasr et al., 2008), self- 
renewal and immortalization require the continuous expres-
sion of the driving oncogene, which endows tumor cells with 
stem  cell  features  (Downing,  2003;  Faber  and Armstrong, 
2007), and the inactivation of which by therapy-induced pro-
tein degradation may be a generally applicable strategy.
PML is an IFN-–induced protein (Stadler et al., 1995) tar-
geted to PML nuclear bodies in an As2O3-dependent manner 
(Zhu et al., 1997). PML was implicated in normal or leukemia 
stem cell self-renewal (Ito et al., 2008). Through PML degrada-
tion, As2O3 may thus directly affect LIC self-renewal (Ito et al., 
2008). Yet, although As2O3 did reduce ATL ability to transplant 
(Fig. 3 C), it never cleared the disease (Fig. 1 F), possibly because 
of insufficient exposure. The IFN-/As2O3 combination seques-
ters PML partner proteins, including Tax, within PML nuclear 
bodies (Lallemand-Breitenbach et al., 2001, 2008; unpublished 
data).  Like  PML, Tax  is  both  sumoylated  and  ubiquitinated   
(Nasr et al., 2006; Lallemand-Breitenbach et al., 2008) and might 
thus be degraded by a PML-dependent mechanism. In addition, 
IFN- forces stem cells into the cell cycle (Essers et al., 2009), 
possibly rendering them more susceptible to As2O3.
Treatment of multi-relapsed, IFN-–resistant, ATL patients 
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Cell cycle analysis and TUNEL assay on isolated splenocytes. ATL 
cells infiltrating the spleen were rapidly harvested, filtered, washed twice with 
cold PBS, fixed in 100% ethanol at 20°C, and kept overnight at 20°C. Subse-
quently, cells were rinsed with PBS, treated with Tris-HCl buffer, pH 7.4, con-
taining 1% DNase-free RNase A, and stained with propidium iodide (60 mg/ml 
final). The distribution of cell cycle phases with different DNA contents was 
determined using a FACScan flow cytometer (BD). In each sample, 10,000 
nongated events were acquired. Analysis of cell cycle distribution (including 
apoptosis) was performed using CellQuest software (BD).
The TUNEL assay was also used to monitor apoptosis of ATL cells infil-
trating the spleen. Splenocytes and ATL cells infiltrating the spleen were rap-
idly collected, filtered, and washed with cold PBS, and the assay was immediately 
performed according to the manufacturer’s (Roche) recommendations.   
Fluorescein-conjugated deoxy-UTP incorporated in nucleotide polymers was 
detected and quantified using flow cytometry. Approximately 10,000 cells per 
sample were acquired and analyzed using CellQuest software.
Quantitative PCR. Spleens were harvested, and real-time PCR or RT-
PCR using a LightCycler (Roche) was used to quantitate the absolute Tax 
DNA content or Tax messenger RNA expression using a LightCycler Fast-
Start DNA Master kit or LightCycler RNA Master kit, respectively. We   
also used the LightCycler software version 4.05 (Roche). Tax primers SK43I 
(5-CGGATACCCAGTCTACGTGT-3) and SK44I (5-GAGCCGATA-
ACGCGTCCATCG-3) and probes SK4I-FL (5-CCCTACTGGCCAC-
CTGTCCAGAGC-FL-3) and SK4I-LC (5-LC Red640-TCAGATC-
ACCTGGGACCCCATCPH-3) were designed in collaboration with 
TIB-MOLBIOL. We also used circulating leukemia cells from two acute 
ATL patients after informed consent. For electrophoretic mobility shift as-
say, nuclear extracts from splenocytes of treated and untreated mice were 
prepared as described previously (El-Sabban et al., 2000).
Statistical  analysis.  Survival  curves  were  calculated  according  to  the 
method of Kaplan–Meier. Overall survival is defined as the time from injec-
tion of ATL cells to death from any cause. Mice that were still alive were cen-
sored at the time they were last known to be alive. Analyses were performed 
using SPSS software version 15.0 (SPSS). The p-value was obtained by log-
rank statistical analysis.
Online supplemental material. Fig. S1 shows the effect of short therapy 
with IFN- and As2O3. Fig. S2 shows the effect of prolonged therapy with 
IFN- and As2O3. Fig. S3 shows that loss of leukemia-initiating activity   
accounts for the therapeutic effect of the IFN- + As2O3 combination.   
Table S1 lists the follow up of ATL patients in complete remission after stop-
ping treatment. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20101095/DC1.
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